<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="T4" position="float">
 <label>Table 4</label>
 <caption>
  <p> Drags targeting SARS-CoV-2 and host immunity included in the article.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th valign="top" align="left" rowspan="1" colspan="1">
     <bold>Therapeutic target</bold>
    </th>
    <th valign="top" align="center" rowspan="1" colspan="1">
     <bold>Drug and article reference</bold>
    </th>
    <th valign="top" align="center" rowspan="1" colspan="1">
     <bold>Drugs related studies</bold>
    </th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td valign="top" rowspan="2" align="left" colspan="1">
     <bold>Receptor recognition (ACE2, CD147 receptors)</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Human recombinant soluble form of ACE2 (
     <xref rid="B55" ref-type="bibr">Khan et al., 2017</xref>; 
     <xref rid="B70" ref-type="bibr">Monteil et al., 2020</xref>; 
     <xref rid="B70" ref-type="bibr">Monteil et al., 2020</xref>).
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">NCT04335136, NCT04375046 NCT04287686 (withdrawn)</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Meplazumab (mAb antiCD147 receptor) (
     <xref rid="B101" ref-type="bibr">Wang K. et al., 2020</xref>)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">NCT04275245</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Clathrin-mediated endocytosis</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Hydroxychloroquine (Hq) sulphate (
     <xref rid="B72" ref-type="bibr">Picot et al., 1993</xref>; 
     <xref rid="B50" ref-type="bibr">Jang et al., 2006</xref>; 
     <xref rid="B9" ref-type="bibr">Bender et al., 2020</xref>) and Chloroquine phosphate (
     <xref rid="B84" ref-type="bibr">Savarino et al., 2003</xref>; 
     <xref rid="B98" ref-type="bibr">Vincent et al., 2005</xref>)
     <break/>*multiple targets: clathrin-mediated endocytosis, endosomal Ph, TLR7/8, IFN response, and proinflammatory cytokines release)
     <break/>Controversial results: (
     <xref rid="B13" ref-type="bibr">Borba et al., 2020</xref>; 
     <xref rid="B59" ref-type="bibr">Lane et al., 2020</xref>; 
     <xref rid="B85" ref-type="bibr">Shamshirian et al., 2020</xref>; 
     <xref rid="B97" ref-type="bibr">Tu et al., 2020</xref>)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">-ongoing studies NCT04315948, DisCoVeRy trial, NCT04304053 ChiCTR2000029803, NCT04334148,ChiCTR2000029609
     <bold>
      <sup>-</sup>
     </bold>
     <break/>
     <bold>-</bold>discontinued study: Hq arm of Solidarity trial
     <break/>-withdrawn: NCT04347512, NCT04371926
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">Baricitinib (
     <xref rid="B80" ref-type="bibr">Richardson et al., 2020</xref>; 
     <xref rid="B91" ref-type="bibr">Stebbing et al., 2020</xref>)
     <break/>Ruxolitinib (
     <xref rid="B34" ref-type="bibr">Gaspari et al., 2020</xref>; 
     <xref rid="B113" ref-type="bibr">Yeleswaram et al., 2020</xref>)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">NCT04320277, NCT04401579 NCT04362137</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Endosomal fusion</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Umifenovir (
     <xref rid="B27" ref-type="bibr">Deng et al., 2020</xref>; 
     <xref rid="B63" ref-type="bibr">Lian et al., 2020</xref>)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">IRCT20151227025726N15</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">Camostat mesylate (
     <xref rid="B53" ref-type="bibr">Kawase et al., 2012</xref>; 
     <xref rid="B109" ref-type="bibr">Yamamoto et al., 2016</xref>; 
     <xref rid="B44" ref-type="bibr">Hoffmann et al., 2020b</xref>)
     <break/>* multiple targets: TMPRSS2, endosomal fusion
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">NCT04321096</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Viral synthesis</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Protease inhibitors: lopinavir/darunavir/ritonavir
     <break/>(3CLpro, PLpro)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">RECOVERY trial, NCT04251871, NCT04255017, ChiCTR2000029539 NCT04252274, NCT04295551, ChiCTR2000029308, NCT04252274</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">Remdesivir * (
     <xref rid="B86" ref-type="bibr">Sheahan et al., 2017</xref>; 
     <xref rid="B2" ref-type="bibr">Agostini et al., 2018</xref>; 
     <xref rid="B7" ref-type="bibr">Beigel et al., 2020</xref>; 
     <xref rid="B37" ref-type="bibr">Goldman et al., 2020</xref>; 
     <xref rid="B40" ref-type="bibr">Grein et al., 2020</xref>; 
     <xref rid="B103" ref-type="bibr">Wang M. et al., 2020</xref>; 
     <xref rid="B105" ref-type="bibr">Wu et al., 2020a</xref>; 
     <xref rid="B104" ref-type="bibr">Wang Y. et al., 2020</xref>)
     <break/>*multiple targets: viral autophagy, mTORC1, Nsp12-RdRp, replicase/transcription complex â€“RTC
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Trial ACTT-NCT04280705 si ACTT-II, NCT04292899
     <break/>NCT04257656, SIMPLE trial, WHO Solidarity trial, DisCoVeRy trial
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">Favipiravir/target: Nsp12-RdRp) (
     <xref rid="B22" ref-type="bibr">Coomes and Haghbayan, 2020</xref>)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">ChiCTR2000030254, ChiCTR2000029544 ChiCTR2000029600</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Cytokine response, Th1 response</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">IFN administration (
     <xref rid="B47" ref-type="bibr">Hung et al., 2020</xref>)
     <break/>Controversial results (
     <xref rid="B33" ref-type="bibr">Gandhi, 2020</xref>)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">See 
     <xref rid="T1" ref-type="table">
      <bold>Table 1</bold>
     </xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">Ruxolitinib (anti-Janus kinase inhibitor) (
     <xref rid="B34" ref-type="bibr">Gaspari et al., 2020</xref>; 
     <xref rid="B113" ref-type="bibr">Yeleswaram et al., 2020</xref>)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">NCT04362137</td>
   </tr>
   <tr>
    <td valign="top" rowspan="2" align="left" colspan="1">
     <bold>IL-6 production</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Tocilizumab (
     <xref rid="B108" ref-type="bibr">Xu et al., 2020</xref>). (Anti IL-6 mAb)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">NCT04317092, NCT04315480 COVACTA, NCT04320615</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Sarilumab and siltuximab (Anti IL-6 mAb)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">NCT04324073, NCT04315298, NCT04329650</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>VEGFA</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Bevacizumab (anti-VEGFA mAb)</td>
    <td valign="top" align="left" rowspan="1" colspan="1">NCT04275414</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>GM-CSF</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Gimsilumab (
     <xref rid="B120" ref-type="bibr">Zhou Y. et al., 2020</xref>) (anti GM-CSF mAb)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">BREATH clinical trial</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Inflammatory response</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Corticosteroids (
     <xref rid="B45" ref-type="bibr">Horby et al., 2020</xref>; 
     <xref rid="B106" ref-type="bibr">Wu et al., 2020b</xref>).
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">UK RECOVERY trial NCT04381936</td>
   </tr>
   <tr>
    <td valign="top" rowspan="3" align="left" colspan="1">
     <bold>Immuno-modulatoy activity</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Mesenchymal stem cells (
     <xref rid="B87" ref-type="bibr">Shi et al., 2018</xref>; 
     <xref rid="B60" ref-type="bibr">Leng et al., 2020</xref>)/
     <break/>*multiple targets:inflammatory cytokines, Th2 response, regeneration of damaged cell
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">See 
     <xref rid="T2" ref-type="table">
      <bold>Table 2</bold>
     </xref>
    </td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Thalidomide</td>
    <td valign="top" align="left" rowspan="1" colspan="1">NCT04273529, NCT04273581</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">Fingolimod</td>
    <td valign="top" align="left" rowspan="1" colspan="1">NCT04280588</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1">
     <bold>Neutralizing antibodies</bold>
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">Convalescent plasma (
     <xref rid="B81" ref-type="bibr">Rogers et al., 2020</xref>; 
     <xref rid="B118" ref-type="bibr">Zhou and Zhao, 2020</xref>)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">NCT04381936, NCT04373460, ISRCTN50189673, NCT04348656</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">mAb (
     <xref rid="B92" ref-type="bibr">Sui et al., 2004</xref>; 
     <xref rid="B28" ref-type="bibr">Elshabrawy et al., 2012</xref>); neutralizing IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2 (LY-CoV555) JS016
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">NCT04427501, NCT04441918</td>
   </tr>
   <tr>
    <td valign="top" align="left" rowspan="1" colspan="1"/>
    <td valign="top" align="left" rowspan="1" colspan="1">-cross-reactive neutralizing antibodies against SARS-CoV-2 RBD specific epitopes (
     <xref rid="B58" ref-type="bibr">Lan et al., 2020</xref>; 
     <xref rid="B102" ref-type="bibr">Wang C. et al., 2020</xref>; 
     <xref rid="B115" ref-type="bibr">Yuan et al., 2020</xref>)
    </td>
    <td valign="top" align="left" rowspan="1" colspan="1">See 
     <xref rid="T3" ref-type="table">
      <bold>Table 3</bold>
     </xref>
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
